7,7-二氟-3-氮杂双环[4.1.0]庚烷盐酸盐 | 1376248-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 中文名称: 7,7-二氟-3-氮杂双环[4.1.0]庚烷盐酸盐
• 英文名称: 7,7-difluoro-3-azabicyclo[4.1.0]heptane hydrochloride
• 英文别名: 7,7-Difluoro-3-azabicyclo[4.1.0]heptane hydrochloride；7,7-difluoro-3-azabicyclo[4.1.0]heptane;hydrochloride
• CAS: 1376248-54-2
• 化学式: C₆H₉F₂N*ClH
• mdl: MFCD22056345
• 分子量: 169.602
• InChiKey: CUYZXBBHHFLWRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.46
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-BOC-1,2,3,6-四氢吡啶 在 盐酸 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 生成 7,7-二氟-3-氮杂双环[4.1.0]庚烷盐酸盐
  参考文献：
  名称：

  革-二氟环丙烷部分胺的克级合成

  摘要：

  描述了使用三氟甲基（三甲基）硅烷/碘化钠[CF 3 SiMe 3 -NaI]系统通过不饱和N- Boc衍生物的二氟环丙烷化合成带有宝石-二氟环丙烷部分的单环，螺环和稠合双环仲胺。确定了底物反应性的相对顺序。结果表明，对于反应性烯烃，可以使用标准反应条件，而对于低反应性的底物，则需要缓慢添加Ruppert-Prakash试剂。

  DOI：

  10.1002/adsc.201700857

文献信息

• [EN] PYRIDYL OR PYRAZINYL COMPOUNDS CARRYING A METHYL-BOUND ALPHA-AMINO ACID AMIDE GROUP<br/>[FR] COMPOSÉS PYRIDYLE OU PYRAZINYLE PORTANT UN GROUPE AMIDE D'ACIDE ALPHA-AMINÉ LIÉ À UN MÉTHYLE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2017050807A1

  公开（公告）日：2017-03-30

  The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl- bound N-amide moiety derived from an α-amino acid of formula I where the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, and to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT2C receptor.

  本发明涉及携带自公式I中α-氨基酸衍生的甲基结合N-酰胺基团的吡啶基或吡嗪基化合物，其中变量如权利要求和说明中所定义。该发明还涉及含有这些化合物的药物组合物，以及它们作为5-HT2C受体的调节剂，特别是激动剂或部分激动剂的用途，以及它们用于制备用于预防或治疗对5-HT2C受体调节产生反应的疾病和紊乱的用途。
• Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
  申请人：Nurix Therapeutics, Inc.

  公开号：US11530229B2

  公开（公告）日：2022-12-20

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

  本发明公开了用于抑制泛素蛋白酶体途径中的 E3 酶 Cbl-b 的化合物、组合物和方法。这些化合物、组合物和方法可用于调节免疫系统，治疗免疫系统可调节的疾病，以及体内、体外或体外细胞的治疗。还公开了包含 Cbl-b 抑制剂和癌症疫苗的药物组合物，以及使用 Cbl-b 抑制剂和癌症疫苗治疗癌症的方法；以及包含 Cbl-b 抑制剂和溶瘤病毒的药物组合物，以及使用 Cbl-b 抑制剂和溶瘤病毒治疗癌症的方法。
• PYRIDYL OR PYRAZINYL COMPOUNDS CARRYING A METHYL-BOUND ALPHA-AMINO ACID AMIDE GROUP
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：EP3353155A1

  公开（公告）日：2018-08-01
• CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF
  申请人：Nurix Therapeutics, Inc.

  公开号：US20210053986A1

  公开（公告）日：2021-02-25

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.
• [EN] CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF<br/>[FR] COMPOSÉS CYANO-CYCLOBUTYLE POUR L'INHIBITION DE CBL-B ET LEURS UTILISATIONS
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2020236654A1

  公开（公告）日：2020-11-26

  Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.